Abstract Breast cancer is a malignant tumor that seriously affects the physical and mental health of women. The morbidity and mortality rates rank the first and fifth among female malignant tumors in China, respectively. The multidisciplinary treatment strategies including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy have significantly improved the prognoses of patients with breast cancer. Radiotherapy plays an important role in reducing the tumor recurrence and prolonging the survival of patients who have received breast-conserving surgery or mastectomy. Moreover, it also serves as an effective palliative therapy for inoperable locally advanced or metastatic breast cancer. At present, there is no consensus on the standard guideline for breast cancer radiotherapy in China. In 2020, Radiation Oncology Physicians Branch of Chinese Medical Doctor Association proposed the Radiotherapy Guidelines for Breast Cancer. The Guidelines were formulated based on the latest evidences in combination with national practice in China, aiming to guide the implementation of radiotherapy, and promote the standardization of radiotherapy in breast cancer; and ultimately achieve the goal of making progress in the practice of radiotherapy and improving the prognoses of breast cancer patients.
Corresponding Authors:
Li Yexiong,Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021, China,Email:yexiong@yahoo.com
Cite this article:
Radiation Oncology Physicians Branch of Chinese Medical Doctor Association. Guidelines for radiotherapy of breast cancer (Chinese Medical Doctor Association 2020 edition)[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 321-342.
Radiation Oncology Physicians Branch of Chinese Medical Doctor Association. Guidelines for radiotherapy of breast cancer (Chinese Medical Doctor Association 2020 edition)[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 321-342.
[1] Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4):452-478. DOI:10.6004/jnccn.2020.0016. [2] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8):609-680. DOI:10.19401/j.cnki.1007-3639.2019.08.009. Breast Cancer Committee of the Chinese Anti-Cancer Association. Guidelines and norms for diagnosis and treatment of breast cancer of the Chinese anti-cancer association (2019 edition)[J]. Chin J Oncol, 2019, 29(8):609-680. DOI:10.19401/j.cnki.1007-3639.2019.08.009. [3] Moran MS, Schnitt SJ, Giuliano AE, et al. Society of surgical oncology-american society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer[J]. J Clin Oncol, 2014, 32(14):1507-1515. DOI:10.1200/JCO.2013.53.3935. [4] Morrow M, Van Zee KJ, Solin LJ, et al. Society of surgical oncology-American society for radiation oncology-American society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in Situ[J]. Ann Surg Oncol, 2016, 23(12):3801-3810. DOI:10.1245/s10434-016-5449-z. [5] Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01):10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1385-1393. DOI:10.1016/S1470-2045(18)30380-2. [6] Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs. no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis:the ACOSOG Z0011(alliance) randomized clinical trial[J]. JAMA, 2017, 318(10):918-926. DOI:10.1001/jama.2017.11470. [7] Frasier LL, Holden S, Holden T, et al. Temporal trends in postmastectomy radiation therapy and breast reconstruction associated with changes in national comprehensive cancer network guidelines[J]. JAMA Oncol, 2016, 2(1):95–101. DOI:10.1001/jamaoncol.2015.3717. [8] Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation[J]. N Engl J Med, 2002, 347(8):567-575. DOI:10.1056/NEJMoa020128. [9] Wang SL, Fang F, Hu C, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era:a multicentre randomized controlled trial from China[J]. J Clin Oncol, 2020, 38(31):3604-3614. DOI:10.1200/JCO.20.01024. [10] Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast cancer cooperative group 82b trial[J]. N Engl J Med, 1997, 337(14):949-955. DOI:10.1056/NEJM199710023371401. [11] Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:danish breast cancer cooperative group DBCG 82c randomised trial[J]. Lancet, 1999, 353(9165):1641-1648. DOI:10.1016/S0140-6736(98)09201-0. [12] Taghian AG, Jeong JH, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy:results from five national surgical adjuvant breast and bowel project randomized clinical trials[J]. J Clin Oncol, 2006, 24(24):3927-3932. DOI:10.1200/JCO.2006.06.9054. [13] McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:meta-analysis of individual patient data for 8135 women in 22 randomised trials[J]. Lancet, 2014, 383(9935):2127-2135. DOI:10.1016/S0140-6736(14)60488-8. [14] Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer[J]. N Engl J Med, 2015, 373(4):317-327. DOI:10.1056/NEJMoa1415369. [15] Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer[J]. N Engl J Med, 2015, 373(4):307-316. DOI:10.1056/NEJMoa1415340. [16] Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN:a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer[J]. J Clin Oncol, 2016,34(4):314-320. DOI:10.1200/JCO.2015.63.6456. [17] Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer:a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3):352-360. DOI:10.1016/S1470-2045(18)30813-1. [18] Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation[J]. J Clin Oncol. 2002, 20(1):17-23. DOI:10.1200/JCO.2002.20.1.17. [19] Garg AK, Strom EA, McNeese MD, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage Ⅱ breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):138-145. DOI:10.1016/j.ijrobp.2003.10.037. [20] McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy[J]. Int J Radiat Oncol Biol Phys, 2007, 68(4):1004-1009. DOI:10.1016/j.ijrobp.2007.01.023. [21] Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy:results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27[J]. J Clin Oncol, 2012, 30(32):3960-3966. DOI:10.1200/JCO.2011.40.8369. [22] Woodward WA, Fang P, Arriaga L, et al. A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(4):777-783. DOI:10.1016/j.ijrobp.2017.04.030. [23] Thomas A, Khan SA, Chrischilles EA, et al. Initial surgery and survival in stage ⅠV breast cancer in the United States, 1988-2011[J]. JAMA Surg, 2016, 151(5):424-431. DOI:10.1001/jamasurg.2015.4539. [24] Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer:an open-label randomised controlled trial[J]. Lancet Oncol, 2015, 16(13):1380-1388. DOI:10.1016/S1470-2045(15)00135-7. [25] Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage ⅠV breast cancer at presentation:protocol MF07-01[J]. Ann Surg Oncol, 2018, 25(11):3141-3149. DOI:10.1245/s10434-018-6494. [26] Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases[J]. J Natl Cancer Inst, 2005, 97(11):798-804. DOI:10.1093/jnci/dji139. [27] Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases:ASCO clinical practice guideline update[J]. J Clin Oncol, 2018, 36(27):2804-2807. DOI:10.1200/JCO.2018.79.2713. [28] Tsao MN, Xu W, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases[J]. Cochrane Database Syst Rev, 2018, 1(1):CD003869. DOI:10.1002/14651858. CD003869.pub4. [29] Trovo M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer:results of a prospective phase Ⅱ trial[J]. Radiother Oncol, 2018, 126(1):177-180. DOI:10.1016/j.radonc.2017.08.032. [30] Neuman HB, Schumacher JR, Francescatti AB, et al. Risk of synchronous distant recurrence at time of locoregional recurrence in patients with stage Ⅱ and Ⅲ breast cancer (AFT-01)[J]. J Clin Oncol, 2018, 36(10):975-980. DOI:10.1200/JCO.2017.75.5389. [31] Arthur DW, Winter KA, Kuerer HM, et al. NRG oncology-radiation therapy oncology group study 1014:1-year toxicity report from a phase 2 study of repeat breast-preserving surgery and 3-dimensional conformal partial-breast reirradiation for in-breast recurrence[J]. Int J Radiat Oncol Biol Phys, 2017, 98(5):1028-1035. DOI:10.1016/j.ijrobp.2017.03.016. [32] Kim BH, Kwon J, Kim K. Evaluation of the benefit of radiotherapy in patients with occult breast cancer:a aopulation-based analysis of the SEER database[J]. Cancer Res Treat, 2018, 50(2):551-561. DOI:10.4143/crt.2017.189. [33] 邵志敏,沈镇宙,徐兵河. 乳腺肿瘤学[M]. 2版. 上海:复旦大学出版社,2018:763. Shao ZM, Shen ZZ, Xu BH. Breast oncology[M]. 2nd Ed. Shanghai:Fudan University Press, 2018:763. [34] Furet E, Peurien D, Fournier-Bidoz N, et al. Plastic surgery for breast conservation therapy:how to define the volume of the tumor bed for the boost?[J]. Eur J Surg Oncol, 2014, 40(7):830-834. DOI:10.1016/j.ejso.2014.03.009. [35] Kaidar-Person O, Vrou Offersen B, Hol S, et al. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer[J]. Radiother Oncol, 2019, 137:159-166. DOI:10.1016/j.radonc.2019.04.010. [36] Taylor CW, Wang Z, Macaulay E, et al. Exposure of the heart in breast cancer radiation therapy:a systematic review of heart doses published during 2003 to 2013[J]. Int J Radiat Oncol Biol Phys, 2015, 93(4):845-853. DOI:10.1016/j.ijrobp.2015.07.2292.
2021, Vol. 30 
